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Background. The administration of short-acting opioids can be a reliable and safe method to
prevent coughing during emergence from anaesthesia but the proper dose or effect site con-
centration of remifentanil for this purpose has not been reported. We therefore investigated
the effect site concentration (Ce) of remifentanil for preventing cough during emergence from
anaesthesia with propofol–remifentanil target-controlled infusion.
Methods. Twenty-three ASA I–II grade female patients, aged 23–66 yr undergoing elective
thyroidectomy were enrolled in this study. EC50 and EC95 of remifentanil for preventing cough
were determined using Dixon’s up-and-down method and probit analysis. Propofol effect site
concentration at extubation, mean arterial pressure, and heart rate (HR) were compared in
patients with smooth emergence and without smooth emergence.
Results. Three out of 11 patients with remifentanil Ce of 1.5 ng ml21 and all seven patients
with Ce of 2.0 ng ml21 did not cough during emergence; the EC50 of remifentanil that sup-
pressed coughing was 1.46 ng ml21 by Dixon’s up-and-down method, and EC95 was 2.14 ng
ml21 by probit analysis. Effect site concentration of propofol at awakening was similar in
patients with a smooth emergence and those without smooth emergence, but HR and arterial
pressure were higher in those who coughed during emergence. Clinically significant hypoventi-
lation was not seen in any patient.
Conclusions. We found that the EC95 of effect site concentration of remifentanil to suppress
coughing at emergence from anaesthesia was 2.14 ng ml21. Maintaining an established Ce of
remifentanil is a reliable method of abolishing cough and thereby targeting smooth emergence
from anaesthesia.
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Various techniques have been proposed as ways of redu-
cing coughing during emergence including deep extuba-
tion,1 the administration of dexmedotomidine,2 i.v. or
topical lidocaine,3 4 or lidocaine applied inside the tracheal
tube cuff.5 Each method has its limitations.
Of the techniques proposed, the administration of short-
acting opioids is promising as it can be maintained during
emergence and the effects are short-lived. Although there
are data regarding the beneficial effect of opioids for
suppressing cough during emergence,6–8 no study has
presented the proper dose or effect site concentration of
remifentanil for preventing cough during emergence. We
therefore hypothesized that maintaining an optimum effect
site concentration of remifentanil by target-controlled infu-
sion (TCI) could safely and effectively suppress cough
during emergence.
The purpose of this study was to evaluate the EC50 and
EC95 of remifentanil in effect-site TCI for preventing
cough in total i.v. anaesthesia (TIVA) with propofol and
remifentanil.
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Methods
After approval from the institutional ethics committee,
written informed consent was obtained from 23 patients (all
females, ASA I–II, aged 23–66 yr undergoing general
anaesthesia for elective thyroidectomy compared with
thyroid neoplasm) who were enrolled in this study.
Exclusion criteria were signs of difficult airway, increased
risk of perioperative aspiration, history of chronic respiratory
disease such as chronic obstructive pulmonary disease or
asthma, recent respiratory tract infection, current smokers,
and significant cardiovascular, hepatic, or renal disease.
All patients were premedicated with midazolam 0.05
mg kg21 i.m. 30 min before and glycopyrrolate 0.5 mg
i.v. just before induction of anaesthesia. ECG, SpO2, E
0
CO2
,
non-invasive blood pressure (NIBP), and nasopharyngeal
temperature were monitored at 1–5 min intervals.
For effect-site TCI of propofol and remifentanil, a com-
mercial TCI pump (Orchestraw Base Primea, Fresenius
Vial, France) was used, and the pumps were operated by
Schnider and colleagues’9 and Minto and colleagues’10
models for propofol and remifentanil, respectively; our
protocol was based on targeted effect site concentration
rather than measured plasma concentration from direct
sampling.
Anaesthesia was induced using targeted effect-site TCI
remifentanil and propofol. After the patient was unable to
respond to verbal stimulus, rocuronium 1 mg kg21 was
given i.v. Tracheal intubation was performed in all patients
using a 7.0 mm [internal diameter (I.D.)] reinforced endo-
tracheal tube and cuff pressure was maintained at 20–
25 mm Hg throughout the procedure. Mechanical venti-
lation was maintained with a tidal volume of 8 ml kg21,
and ventilatory frequency was adjusted to maintain E0CO2 at
4.6–5.2 kPa. Temperature was maintained at 36–378C.
The effect-site TCI of propofol and remifentanil was
titrated to maintain blood pressure and heart rate (HR)
within 10–20% of pre-induction values, and was kept
within the range of 2.5–4 mg ml21 and 2–5 ng ml21,
respectively.
Two practitioners were involved during the emergence
phase. The first anaesthetist controlled the TCI pump
and recorded the effect site concentration of propofol and
remifentanil, the E0CO2 of the patient during extubation, and
arterial pressure and HR during emergence. The second
anaesthetist, who was blinded to the patients’ effect site
concentration of remifentanil and propofol, was instructed
to extubate the patient, and record the number of coughs
and other adverse events during the emergence phase.
During skin suture, effect-site TCI of remifentanil was
titrated to a predetermined concentration (initial concen-
tration being 1.5 ng ml21 for the first patient). The prede-
termined concentration was maintained throughout
emergence until extubation for at least 15 min, so that
effect site concentration and plasma concentration can be
expected to be stable. After completion of suture, ketorolac
0.5 mg kg21 (maximum dose 30 mg) was given for pain
control and glycopyrrolate 0.004 mg kg21 with neostig-
mine 0.02 mg kg21 was given for reversal of neuromuscu-
lar block, which was confirmed as more than 90%
response of train-of-four (TOF). Propofol was then titrated
to 1.5 mg ml21 effect-site TCI. After the surgical dressings
were applied, propofol infusion was discontinued.
Mechanical ventilation was then converted to manual ven-
tilation and PE0CO2 was maintained at 4.9–6.3 kPa. The
patient was not disturbed, other than continuous verbal
requests to open their eyes, and all other stimulus was
avoided. When the patients opened their eyes, deep breath-
ing was encouraged, and after spontaneous respiration and
adequate tidal volume and ventilatory frequency were con-
firmed, the trachea was extubated. Immediately after extu-
bation, oxygen was supplemented via a facemask for 5
min. Hypoventilation, defined as RR,8 bpm or a SpO2
below 95% despite oxygen supplement, and other respirat-
ory complications were recorded. HR and mean arterial
pressure (MAP) during emergence were recorded at three
points—at the point when remifentanil TCI reached the
predetermined concentration, before, and after immediate
extubation.
Cough was defined as a strong and sudden contraction
of the abdomen. If the patient did not cough during emer-
gence, the extubation was defined as a smooth emergence,
and the predetermined concentration for the subsequent
patient was decreased by 0.5 ng ml21. Similarly, if the
patient coughed anytime around extubation, it was con-
sidered a failed smooth emergence and the predetermined
concentration was increased by 0.5 ng ml21 for the next
patient. After extubation, patients received 100% oxygen
by facemask and were observed for 5 min, and then trans-
ferred to the post-anaesthetic care unit (PACU). In the
PACU, the post-anaesthetic recovery scores11 were
recorded, and fentanyl 1 mg kg21 was given when pain
scores exceeded 5 by visual analogue scales.
Patient data are presented as median and range or mean
(SD). The Dixon’s up-and-down method needs at least six
pairs of smooth emergence–failed smooth emergence for
statistical analysis,12 and 23 patients were collected on the
basis of Dixon’s method. EC50 was defined as the mean of
the cross-over concentrations. The smooth emergence–
failed smooth emergence sequences were also analysed by
the probit test, which enabled us to derive the remifentanil
effect site concentration for cough suppression, with 95%
confidence limits of the mean. Comparison between smooth
emergence patients and failed smooth emergence patient
for propofol effect site concentration at extubation, PE0CO2 at
extubation, recovery score at admission, duration of PACU
stay was performed using Fisher’s exact test of x2 analysis.
MAP and HR during emergence between smooth emer-
gence patients and failed smooth emergence patients were
analysed by RMANOVA. SPSS package (version 13.0,
SPSS Inc., Chicago, IL, USA) was used for statistical analy-
sis. P,0.05 was considered to be statistically significant.
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Results
We enrolled 23 female patients of median age 57 (range
23–66) yr and weight 55 (44–70) kg. Anaesthesia lasted a
median 147 (range 94–255) min. The sequences of
smooth emergence and failed smooth emergence are
shown in Figure 1. Smooth emergence was observed in
three out of 11 patients with effect-site concentration (Ce)
of remifentanil 1.5 ng ml21 and seven out of seven
patients with Ce 2.0 ng ml21. By Dixon’s method, the
EC50 of remifentanil for emergence without cough was
1.46 (SD 0.39) ng ml21. A logistic regression curve of the
probability of no coughing showed that the 50% effective
concentration for abolishing cough during emergence was
1.53 ng ml21 (95% CI 1.18–1.81 ng ml21), and the 95%
effective concentration was 2.14 ng ml21 (95% CI 1.89–
3.57 ng ml21). Significant respiratory complications
including hypoventilation did not occur in any of the
patients. Emergence profile between smooth emergence
patients and failed smooth emergence patients are com-
pared in Table 1. Both groups were comparable with awa-
kening effect site concentration of propofol, recovery score
at admission, and duration of stay in the PACU.
Haemodynamic values of smooth emergence and failed
smooth emergence patients are compared in Table 2. MAP
and HR were statistically higher in failed smooth emer-
gence patients who had coughed during emergence
(P¼0.002 and P¼0.038, respectively).
Discussion
In this study we used propofol–remifentanil TIVA with the
goal of finding the effect site concentration of remifentanil
for smooth emergence. Our results show that the EC95 of
remifentanil that abolishes cough during emergence is 2.14
ng ml21. Several studies have demonstrated the use of
opioids for preventing cough. During propofol anaesthesia,
fentanyl modified airway reflexes and decreased the
incidence of cough in a dose-related manner6 and during
isoflurane anaesthesia, fentanyl 2 mg kg21 7 or alfentanil 15
mg kg21 8 effectively attenuated cough and cardiovascular
stimulation during emergence. However, a bolus dose of
remifentanil 1 mg kg21 attenuated the increase in blood
pressure and HR during emergence, but failed to demonstrate
a decrease in the incidence of cough.13 The antitussive effect
of opioids is primarily central,14 and maintaining and pre-
dicting a certain plasma or effect site concentration by a
single bolus administration is clinically difficult and unreli-
able, and could be the reason why a single bolus dose of
remifentanil failed to suppress cough during emergence. We
hypothesized that a method which targeted and maintained
the effect site concentration of opioid could be more reliable.
The effect site TCI of remifentanil is desirable in
this setting because the context-sensitive half-life of
remifentanil is short and infusion with a TCI pump
can predict and maintain the target concentration safely
during emergence. It was previously reported that TIVA
with propofol–remifentanil reduce the incidence of cough
during emergence compared with balanced anaesthesia
with fentanyl-sevoflurane-N2O,
15 but the effect site
Table 1 Comparison between smooth emergence patients and failed smooth
emergence patients. Values are expressed as mean (range), mean (SD) or
number. Ce, effect site concentration; E0CO2, end-tidal carbondioxide tensions;
PAR, post-anaesthesia room; PACU, post-anaesthesia care unit. *P,0.05
between groups.
Smooth
emergence
Failed smooth
emergence
Number of patients 11 12
Age 43.8 (23–66) 46.5 (23–66)
Number of coughs 0 3 (3–6)
Propofol Ce at extubation (mg ml21) 1.1 (0.7–1.5) 1.0 (0.8–1.7)
Remifentanil Ce at extubation (ng ml21) 2.0 (1.0–2.0)* 1.5 (0.5–1.5)
PE0CO2 at extubation (kPa) 5.5 (4.9–6.0) 5.3 (4.9–6.3)
PAR score at admission 9.1 (0.6) 8.9 (0.4)
Duration of PACU stay (min) 41.3 (12.2) 39.8 (7.1)
Table 2 Comparison of haemodynamic profiles during extubation between
smooth emergence patients and failed smooth emergence patients. Values are
expressed as mean (SD). T1, time when operation was finished and effect site
concentration of remifentanil was maintained at predetermined concentration;
T2, immediately before extubation; T3, immediately after extubation; MAP,
mean arterial pressure; HR, heart rate. *P¼0.002; †P¼0.038
Smooth
emergence patients
Failed smooth
emergence patients*,†
MAP (mm Hg) T1 82.6 (12.0) 89.8 (13.4)
T2 87.7 (10.1) 95.8 (11.3)
T3 88.4 (8.4) 98.6 (9.7)
HR (beats min21) T1 61.7 (9.2) 66.1 (11.8)
T2 65.7 (9.9) 74.2 (11.5)
T3 66.7 (7.3) 75.7 (10.5)
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Fig 1 Data of consecutive smooth emergence and failed smooth
emergence over predetermined concentration (PRC) of remifentanil (with
initial PRC being 1.5 ng ml21 for the first patient). Seven pairs of smooth
emergence–failed smooth emergence sequences were received for
statistical analysis with the Dixon’s up-and-down method. The effect site
concentration of remifentanil for abolishing emergence cough in 50% of
patients was 1.46 (0.39) ng ml21.
Remifentanil for preventing emergence cough
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concentration of any drugs for preventing cough during
propofol–remifentanil TIVA has not been determined. Our
attention was on the antitussive effect of remifentanil, and
therefore designed this study to demonstrate the remifenta-
nil effect site concentration for preventing cough during
emergence in propofol–remifentanil TIVA. None of the
patients suffered hypoventilation, and all were discharged
from the PACU without any adverse events. The main
reason for delayed discharge was because of administration
of fentanyl 1 mg kg21 for postoperative pain control,
which occurred in six patients in our study. The rapid ces-
sation of remifentanil’s analgesic effect has shown to
increase analgesic drug requirements during the postopera-
tive period,16 and although our study was limited to
thyroid operations, more painful operations are expected to
require more analgesics during recovery and thus may
increase the incidence of other side effects. Further studies
will be required to demonstrate the application of our
result for other types of surgery.
A few limitations in our study should be kept in mind.
First, pharmacodynamic and pharmacokinetic difference
exists between women and men during propofol anaesthe-
sia, and emergence is more rapid in female patients.17 The
study population is limited to females in this study, and
therefore should be considered when interpreting the data.
Secondly, because older patients are more sensitive to
opioids, age variation should also be considered. Since our
patients ranged from 23 to 66 yr, some patient character-
istics should be considered. The mean age of smooth
emergence patients was 43.8 yr and that of failed smooth
emergence was 46.5 yr. It should also be stated that the
oldest patient, aged 66 yr, received an infusion of remifen-
tanil with a predetermined concentration of 1.5, and did
not cough during emergence. We therefore believe that
age variation of remifentanil sensitivity did not interfere
with our data, although when the calculated EC95 value is
clinically applied to older patients than our study groups, a
lower concentration could be required for cough suppres-
sion. Thirdly, the presented concentration is a predicted
value that is calculated from a pharmacokinetic model,
and not real measurement from patients’ plasma sampling.
This predicted that effect site concentration is estimated
from Minto’s pharmacokinetic model, however it is known
that remifentanil can be administered by this method with
acceptable bias and inaccuracy in clinical situations.18
In conclusion, the EC95 of effect site concentration of
remifentanil that suppresses coughing is 2.14 ng ml21.
Maintaining this Ce of remifentanil during emergence is a
safe and reliable method of abolishing cough and thereby
targeting smooth emergence.
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